
Art of Boring
Mawer Investment Management Ltd.
Listen as Mawer Investment Management Ltd. takes a deeper dive into the investment philosophy and strategies that have helped put the odds in their clients' favour for over 50 years.
AI Build-Out: What We Know, What We Don't, and What's in the Stock | EP 236
Episode discussion: Petkovic discusses AI supply constraints, enterprise adoption, and political risks in data center build-out
Speakers’ claims: Irena Petkovic joins the Art of Boring podcast to analyze the current state of the AI build-out following recent market volatility. She argues that hyperscaler growth is now bottlenecked by data center construction speed rather than demand, citing revenue acceleration from Amazon AWS and Google Cloud. Petkovic highlights significant enterprise adoption data from Anthropic's S-1, noting that Fortune 500 spending on AI remains a tiny fraction of total expenses. The discussion also covers the increasing reliance on external financing for infrastructure, potential political headwinds in key states, and the structural shift in internet traffic caused by AI agents bypassing traditional ad models.
Global Small Cap: A New Lead Manager on the Missing Premium, Local Businesses, and Talent Density | EP 235
Episode discussion: Ching Chang on Small Cap Premium Disappearance and Local Business Opportunities
Speakers’ claims: Ching Chang discusses his evolution from value investing to focusing on quality compounding companies, citing his experience at Ontario Teachers' Pension Plan. He attributes the disappearance of the small cap premium to companies staying private longer and large-cap tech firms scaling without capital constraints. Chang views small caps as diversifiers with local business focus rather than expecting a return of the historical premium. He emphasizes the need for regional overlays to manage macro risks and evaluates management teams based on customer focus and talent density.
Consumer Biotech: The Value Chain Beneath the GLP-1 Boom | EP 234
Episode discussion: Episode explores the GLP-1 supply chain, highlighting massive API demand growth and purification bottlenecks.
Speakers’ claims: Joshua Samuel discusses the emergence of 'consumer biotech' driven by GLP-1 drugs reaching 44 million users within five years. He explains how the shift from injectables to oral pills could require 2-10x more active pharmaceutical ingredient (API) due to low bioavailability. The episode highlights that peptide synthesis yields compound over many steps, making process engineering critical. Samuel identifies a purification bottleneck involving silica gel, where one supplier holds ~70% global market share. He argues that drug approvals lock in suppliers, creating durable revenue streams for consumable providers despite their classification as specialty chemical companies.